Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab

European Journal of Ophthalmology

Volumn 22, Issue 4, 2012, Pages 563-574

  Wittström, Elisabeth ^a   Holmberg, Hans ^a   Hvarfner, Charlotte ^a   Andréasson, Sten ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bevacizumab; Full field ERG; Ischemic central retinal vein occlusion; Neovascular glaucoma

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; TIMOLOL MALEATE;

A WAVE; AGED; ARTICLE; B WAVE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; MONOTHERAPY; NEOVASCULAR GLAUCOMA; PANRETINAL PHOTOCOAGULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETINA CONE; RETINA ROD; SENSORY SYSTEM ELECTROPHYSIOLOGY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; FEMALE; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; PHOTORECEPTOR CELLS, VERTEBRATE; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84863752684     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000089     Document Type: Article

References (78)

1. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidencebased recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108: 1767-78.
2. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007; 26: 470-85.
3. Brown GC, Magargal LE, Schachat A, Shah H. Neovascular glaucoma: etiologic considerations. Ophthalmology 1984; 91: 315-20.
4. Magargal LE, Brown GC, Augsburger JJ, Parrish RK II. Neovascular glaucoma following central retinal vein obstruction. Ophthalmology 1981; 88: 1095-101.
5. Evans K, Wishart PK, McGalliard JN. Neovascular complications after central retinal vein occlusion. Eye 1993; 7: 520-4.
6. Wittström E, Ponjavic V, Lövestam-Adrian M, Larsson J, Andréasson S. Electrophysiological evaluation and visual outcome in patients with central retinal vein occlusion, primary open-angle glaucoma and neovascular glaucoma. Acta Ophthalmol 2010; 88: 86-90.
7. Larsson J, Bauer B, Cavallin-Sjöberg U, Andréasson S. Fluorescein angiography versus ERG for predicting the prognosis in central retinal vein occlusion. Acta Ophthalmol Scand 1998; 76: 456-60.
8. Larsson J, Andréasson S, Bauer B. Cone b-wave implicit time as an early predictor of rubeosis in central retinal vein occlusion. Am J Ophthalmol 1998; 125: 247-9.
9. Larsson J, Andréasson S. Photopic 30 Hz flicker ERG as a predictor for rubeosis in central retinal vein occlusion. Br J Ophthalmol 2001; 85: 683-5.
10. Kjeka O, Bredrup C, Krohn J. Photopic 30 Hz flicker electroretinography predicts ocular neovascularization in central retinal vein occlusion. Acta Ophthalmol Scand 2007; 85: 640-3.
11. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic reti nopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
12. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71.
13. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105: 412-6.
14. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998; 105: 232-7.
15. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002; 120: 1644-50.
16. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma 2002; 11: 406-10.
17. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 373-85.
18. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
19. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
20. Cohen M, Gootenberg J, Keegan P, Pazdur R. FDA drag approval summary: Bevacizumab plus FOLFOX4 as secondline treatment of colorectal cancer. Oncologist 2007; 12: 356-61.
21. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006; 26: 383-90.
22. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009; 50: 1025-32.
23. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-9.
24. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 2008; 116: 147-52.
25. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 155-8.
26. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal endothebevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26: 1006-13.
27. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi). Acta Ophthalmol 2008; 86: 385-9.
28. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-8.
29. Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal Bevacizumab for diffuse diabetic macular edema. The Pan-American collaborative retina study group at 24 months. Ophthalmology 2009; 116: 1488-97.
30. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-60.
31. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26: 354-6.
32. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352-4.
33. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054-6.
34. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007; 23: 487-91.
35. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007; 35: 494-6.
36. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol 2009; 93: 589-93.
37. Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol 2008; 66: 667-73.
38. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008; 28: 696-702.
39. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009; 18: 632-7.
40. Vasudev D, Blair MP, Galasso J, Kapur R, Vajaranant T. Intravitreal bevacizumab for neovascular glaucoma. J Ocul Pharmacol Ther 2009; 25: 453-8.
41. Brouzas D, Charakidas A, Moschos M, Koutsandrea C, Apostolopoulos M, Baltatzis S. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin Ophthalmol 2009; 3: 685-8.
42. Lupinacci APC, Calzada JI, Rafieetery M, Charles S, Netland PA. Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab. Adv Ther 2009; 26: 208-16.
43. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol 2009; 19: 607-12.
44. Duch S, Buchacra O, Milla E, Andreu D, Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma. A pilot study in 6 patients. J Glaucoma 2009; 18: 140-3.
45. Ciftci S, Sakalar YB, Unlu K, Keklikci U, Caca I, Dogan E. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma. Eur J Ophthalmol 2009; 19: 1028-33.
46. Beutel J, Peters S, Luke M, et al. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 2010; 88: 103-9.
47. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115: 1571-80.
48. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective observational case series. Arch Ophthalmol 2011; 129: 145-50.
49. Weiss DI, Gold D. Neofibrovascularization of iris and anterior chamber angle: a clinical classification. Ann Ophthalmol 1978; 10: 488-91.
50. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009; 118: 69-77.
51. Cashwell LF, Marks WP. Panretinal photocoagulation in the management of neovascular glaucoma. South Med J 1988; 81: 1364-8.
52. Murdoch IE, Rosen PH, Shilling JS. Neovascular response in ischaemic central retinal vein occlusion after panretinal photocoagulation. Br J Ophthalmol 1991; 75: 459-61.
53. Little HL, Rosethal AR, Dellaporta A, Jacobson DR. The effect of pan-retinal photocoagulation on rubeosis iridis. Am J Ophthalmol 1976; 81: 804-9.
54. Laatikainen L, Kohner EM, Khoury D, Blach RK. Panretinal photocoagulation in central retinal vein occlusion: a randomised controlled clinical study. Br J Ophthalmol 1977; 61: 741-53.
55. Magargal LE, Brown GC, Augsburger JJ, Donoso LA. Efficacy of panretinal photocoagulation in preventing neovascular glaucoma following ischemic central retinal vein obstruction. Ophthalmology 1982; 89: 780-4.
56. Frank RN. Visual fields and electroretinography following extensive photocoagulation. Arch Ophthalmol 1975; 93: 591-8.
57. Perlman I, Gdal-on M, Miller B, Zonis S. Retinal function of the diabetic retina after argon laser photocoagulation assessed electroretinographically. Br J Ophthalmol 1985; 69: 240-6.
58. Yourey PA, Gohari S, Su JL, Alderson RF. Vascular endothebevacizumab lial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci 2000; 20: 6781-8.
59. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, a therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-70.
60. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization. Promises and potential problems. JAMA 2005; 293: 1509-13.
61. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005; 167: 1451-9.
62. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90: 1178-82.
63. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257-61.
64. Ziemssen F, Luke M, Messias A, et al. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2008; 28: 101-9.
65. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 270-4.
66. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007; 48: 1773-81.
67. Stahl A, Feltgen N, Fuchs A, Bach M. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Doc Ophthalmol 2009; 118: 81-8.
68. Shetty R, Pai SA, Vincent A, et al. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 2008; 116: 129-35.
69. Pedersen KB, Möller F, Sjölie AK, Andréasson S. Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. Retina 2010; 30: 1025-33.
70. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002.
71. Ameri H, Chader GJ, Kim J, Sadda SR, Rao NA, Humayun MS. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 2007; 48: 5708-15.
72. Nishijima K, Ng Y, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53-67.
73. Avci B, Avci R, Inan UU, Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 3438-46.
74. Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 2008; 3: e3554.
75. Shima Ch, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008; 86: 372-6.
76. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-9.
77. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-7.
78. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-9.